Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years old or older.~2. A diagnosis of Chronic Lymphocytic Leukemia(CLL) which is CD5/CD19/CD23 positive, confirmed by peripheral blood immunophenotyping and/or lymph node biopsy and immunophenotyping and/or bone marrow biopsy and immunophenotyping. CD23-negative CLL cases are eligible, however additional diagnostic confirmation should include absence of Cyclin D1 rearrangement \[t(11;14)\] as determined by standard laboratory methods (such as fluorescent in situ hybridization).~3. Patients are planning to start chemotherapy for CLL recommended and prescribed by their primary oncologist.~4. Peripheral blood lymphocyte count above 20,000/mm3~5. Be able to provide written informed consent~Exclusion Criteria~1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.~2. Patients who are receiving any other investigational agents.~3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to vincristine.~4. Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~5. Liver function test abnormalities of ≥ grade 3 (total bilirubin \>3 ULN (upper limit of normal), AST\> 5 ULN, ALT\> 5 ULN) as per CTCAE 4.0 criteria, or direct bilirubin ≥ 3.0 mg/dL~6. Pre-existing neuropathy grade 2 or greater as per CTCAE 4.0 criteria (moderate symptoms limiting instrumental activities of daily living - ADLs)~7. Patients who are pregnant or planning to become pregnant during their participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vincrisitne 2mg (Type: EXPERIMENTAL): Single Arm study: Vincristine 2mg administered IV by infusion over 5 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).